A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype

Clinical trial NCT05643495 · TERMINATED

Trial details

NCT number: NCT05643495
Sponsor: Vertex Pharmaceuticals Incorporated
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Alpha-1 Antitrypsin Deficiency

Start date: 2023-02-23
Primary completion: 2024-08-19
Enrollment: 14

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.